Charoentum Chaiyut, Thongprasert Sumitra, Chewaskulyong Busyamas, Munprakan Sutthirak
Department of Medicine, Chiang Mai University, 110 Intawaroros Road, Maung district, Chiang Mai 50200, Thailand.
World J Gastroenterol. 2007 May 28;13(20):2852-4. doi: 10.3748/wjg.v13.i20.2852.
To study the activity of gemcitabine and cisplatin in a cohort of patients with inoperable or metastatic cholangiocarcinoma.
Chemotherapy-naive patients with pathologically proven cholangiocarcinoma, receiving treatment that consisted of gemcitabine at 1250 mg/m(2) in a 30-min infusion on d 1 and 8, and cisplatin at 75 mg/m(2) at every 21-d cycle, were retrospectively analyzed.
From June 2003 to December 2005, 42 patients were evaluated. Twelve patients (28%) had unresectable disease and 30 (72%) had metastatic disease. There were 28 males and 14 females with a median age of 51 years (range 33-67) and median ECOG PS of 1 (range 0-2). A total of 171 cycles were given with a median number of cycles of 4 (range 1-6). There were 0 CR, 9 PR, 11 SD and 13 PD (response rate 21%). Grade 3-4 hematologic toxicities were: anemia in 33%, neutropenia in 22% and thrombocytopenia in 5%. Non-hematologic toxicity was generally mild. No cases of febrile neutropenia or treatment-related death were noted. The median survival was 10.8 mo (range 8.4-13 mo) and progression free survival was 8.5 mo. One-year survival rate was 40%.
Our results indicate that the combination of gemcitabine and cisplatin had consistent efficacy in patients with unresectable or metastatic cholangiocarcinoma.
研究吉西他滨和顺铂在一组无法手术切除或转移性胆管癌患者中的活性。
对未经化疗、经病理证实为胆管癌的患者进行回顾性分析，这些患者接受的治疗方案为：第1天和第8天静脉滴注30分钟，给予吉西他滨1250mg/m²，每21天为一个周期，给予顺铂75mg/m²。
2003年6月至2005年12月，共评估了42例患者。12例（28%）患者疾病无法切除，30例（72%）患者有转移。男性28例，女性14例，中位年龄51岁（范围33 - 67岁），中位东部肿瘤协作组（ECOG）体能状态评分为1分（范围0 - 2分）。共给予171个周期的治疗，中位周期数为4个（范围1 - 6个）。完全缓解（CR）0例，部分缓解（PR）9例，疾病稳定（SD）11例，疾病进展（PD）13例（缓解率21%）。3 - 4级血液学毒性为：贫血33%，中性粒细胞减少22%，血小板减少5%。非血液学毒性一般较轻。未观察到发热性中性粒细胞减少或治疗相关死亡病例。中位生存期为1
